コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ents are incurable and become candidates for investigational therapy.
2 uncontrolled trials may bias them toward an investigational therapy.
3 committee had no record of approval for the investigational therapy.
4 agnosis and management of food allergies and investigational therapies.
5 ir potential to be targeted with approved or investigational therapies.
6 changes as shown by the mfVEP in response to investigational therapies.
7 t from having a liver biopsy and considering investigational therapies.
8 uville 4 should be the focus of risk-adapted investigational therapies.
9 empirical antibiotics; and 23 (85%) received investigational therapies (19 [70%] received at least tw
10 and the immune system have led to many novel investigational therapies and continue to inform efforts
11 bility to determine the potential benefit of investigational therapies and the effect of patient-spec
12 cting patient safety, facilitating access to investigational therapies, and ensuring trial integrity.
13 e relative contributions of supportive care, investigational therapies, and patient's immune-response
16 rams that choose to change patients to other investigational therapies (eg, intensive chemotherapy an
17 ions were observed for patients who received investigational therapy followed by cisplatin-based ther
20 patients receiving 131I anti-B1 therapy, an investigational therapy for non-Hodgkin's lymphoma, indi
21 t, in general, older patients should receive investigational therapy; however, factors other than age
23 l trials are needed to delineate the role of investigational therapies in the care of patients with E
26 anut oral immunotherapy (OIT) is a promising investigational therapy, its potential is limited by sub
28 consent for a trial but before receiving the investigational therapy, participants answered questions
29 an papillomavirus-negative HNSCC, as well as investigational therapies, such as hypoxia modification,
30 gnaling are reviewed along with an update on investigational therapies that use this pathway to rever
31 ications for the application of standard and investigational therapies to patients with ADA-SCID and
33 onsultation, options for standard as well as investigational therapies were discussed, and HLA typing
34 ory CME remains a therapeutic challenge, but investigational therapies with potential include cortico
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。